Endothelin-1 receptor antagonists have been employed in patients with pulmonary hypertension to improve functional status and other indices ofpulmonary hypertension-related morbidity [73], further suggesting that ET-1 isan important mediator of pulmonary vascular dysregulation. Here, EDN1 is linked to pulmonary hypertension.